Related Experiment Video

Updated: May 22, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Genotype impact on long-term virological outcome of chronic hepatitis B virus infection

Sebastian Malmström1, Anders Eilard, Simon B Larsson

  • 1Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|May 22, 2012
PubMed

Insights

Hepatitis B virus (HBV) genotype influences long-term outcomes. Genotypes A, B, and D showed decreased HBV DNA, unlike genotype C. Genotype C infection poses a higher risk for progressive liver damage.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • The clinical significance of hepatitis B virus (HBV) genotypes in chronic infection progression remains unclear.
  • Understanding genotype-specific impacts is crucial for managing chronic HBV.
  • Long-term outcomes associated with different HBV genotypes require further investigation.

Purpose of the Study:

  • To investigate the impact of HBV genotype on the long-term virological outcomes of chronic hepatitis B infection.
  • To compare the sustained viral activity and serological markers across different HBV genotypes.
  • To assess the risk of progressive liver damage based on HBV genotype.

Main Methods:

  • A cohort of 124 adults with chronic HBV infection was followed for a median of 9.2 years.
  • Hepatitis B surface antigen (HBsAg), HBeAg, ALT, and HBV DNA levels were monitored.
  • Genotype analysis was performed, with a subset of 33 patients being HBeAg-positive at baseline.

Main Results:

  • HBV DNA levels significantly decreased in patients with genotypes A, B, and D, but not in those with genotype C.
  • Loss of HBeAg occurred in 44% of genotype C patients versus 92% in non-C genotypes.
  • HBsAg loss was observed in 36% of genotype A, 5% of B, 0% of C, and 11% of D patients.

Conclusions:

  • Chronic HBV infection with genotypes A, B, and D is associated with decreased viral load over time.
  • Highly active infections, particularly with genotype C or D, may persist, indicating a risk for liver damage.
  • Genotype-specific differences in virological response and serological markers are evident in long-term chronic HBV infection.
Abstract

More Related Videos

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...